TNDM Stock Forecast & Price Target

Tandem Diabetes Care has demonstrated a solid financial performance, with revenue estimates for 2026 and 2027 showing slight increases to $1.111 million and $1.229 million, respectively, indicating a stable growth trajectory. The company is expected to return to positive new patient start growth in the U.S., projected at approximately 4% year-over-year, primarily driven by conversions from multiple daily injections (MDI) and enhanced access through pharmacy channels. Additionally, Tandem's revenue beat expectations by about $14 million, largely attributed to increased performance in the U.S. market and pricing advantages from pharmacy channel penetration, further reflecting the potential for sustained profitability growth.

Tandem Diabetes Care has experienced substantial operating losses since its inception, raising concerns about its potential for sustained profitability. The company is facing multiple risks that could negatively impact new patient acquisition in the U.S. market, including increased competition, challenges in securing favorable pharmacy contracts, and uncertainties surrounding the anticipated benefits from its recent product launches. Additionally, despite exceeding shipment estimates, U.S. pump shipments declined by 4% year-over-year, which, combined with lower growth and margins compared to industry peers, contributes to a negative outlook for the company's financial performance.